All In Biotech

BLA 761143 · Horizon Therapeutics Ireland

Tepezza

Teprotumumab-Trbw · Injection · Insulin-like Growth Factor-1 Receptor Inhibitor

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jan 21, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

21

4 Phase 3, 5 recruiting

FAERS reports

5,951

2,588 serious, 41 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 28, 2026.

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration. TEPEZZA is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration ( 1 )

Mechanism: Teprotumumab-trbw's mechanism of action in patients with Thyroid Eye Disease has not been fully characterized. Teprotumumab-trbw binds to IGF-1R and blocks its activation and signaling.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 21, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
  • TEPEZZA · TEPROTUMUMAB-TRBW 500MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Teprotumumab" as an intervention, any sponsor and status, largest first.

All 21 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • muscle spasms1,156
  • fatigue822
  • tinnitus627
  • hypoacusis504
  • headache499
  • diarrhoea462
  • blood glucose increased458
  • nausea453
  • alopecia441
  • endocrine ophthalmopathy375
  • pain360
  • anxiety350

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2020475
2021692
2022727
2023732
20241,869
2025702
2026754

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tepezza (Teprotumumab-Trbw)

2024 spending

$152M

Beneficiaries

515

2,708 claims

Per beneficiary

$294,974

$14,094.61 per unit

View as table
YearSpending
2020$42,287,713
2021$61,244,125
2022$90,892,963
2023$129,065,494
2024$151,911,672

Part B: Tepezza (Teprotumumab-Trbw) · HCPCS J3241

2024 spending

$246M

Beneficiaries

962

5,046 claims

Per beneficiary

$256,201

2024 ASP limit $335.36 per unit

View as table
YearSpending
2020$65,401,279
2021$302,693,259
2022$308,126,858
2023$273,505,773
2024$246,465,795

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 33 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.